Voclosporin
Phase 2Terminated 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Focal Segmental Glomerulosclerosis
Conditions
Focal Segmental Glomerulosclerosis
Trial Timeline
Jun 21, 2018 → May 19, 2020
NCT ID
NCT03598036About Voclosporin
Voclosporin is a phase 2 stage product being developed by Aurinia Pharmaceuticals for Focal Segmental Glomerulosclerosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT03598036. Target conditions include Focal Segmental Glomerulosclerosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05962788 | Phase 3 | Terminated |
| NCT03598036 | Phase 2 | Terminated |
| NCT02949999 | Phase 1 | Completed |
| NCT02949973 | Phase 2 | Completed |
| NCT00258713 | Phase 3 | Completed |
Competing Products
20 competing products in Focal Segmental Glomerulosclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| OnabotulinumtoxinA 145 UNT [Botox] | AbbVie | Approved | 85 |
| Dapagliflozin | AstraZeneca | Approved | 85 |
| Enfuvirtide + Tenofovir-Emtricitabine | Roche | Phase 2 | 52 |
| CCX140-B | Amgen | Phase 2 | 51 |
| PF-06730512 | Pfizer | Phase 2 | 51 |
| Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide | Pfizer | Approved | 84 |
| VX-147 | Vertex Pharmaceuticals | Phase 2 | 51 |
| VX-147 | Vertex Pharmaceuticals | Phase 1 | 32 |
| IXP | Vertex Pharmaceuticals | Phase 1 | 32 |
| fresolimumab + fresolimumab + Placebo | Sanofi | Phase 2 | 51 |
| GC1008 + GC1008 + GC1008 + GC1008 | Sanofi | Phase 1 | 32 |
| frexalimab + brivekimig + rilzabrutinib + placebo | Sanofi | Phase 2 | 51 |
| Vivaglobin | CSL | Phase 2 | 51 |
| UCB0942 | UCB | Phase 2 | 49 |
| Levetiracetam + Carbamazepine + Lamotrigine | UCB | Approved | 82 |
| Brivaracetam + Brivaracetam | UCB | Phase 2 | 49 |
| Lacosamide | UCB | Phase 2 | 49 |
| UCB0942 + UCB0942 + Placebo | UCB | Phase 2 | 49 |
| Lacosamide | UCB | Pre-clinical | 20 |
| ARGX-117 | Argenx | Phase 2 | 49 |